← Browse by Condition
Medical Condition

sickle cell disease

Total Trials
13
Recruiting Now
13
Trial Phases
Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for sickle cell disease sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — sickle cell disease Clinical Trials

How many clinical trials are currently recruiting for sickle cell disease?
ClinicalMetric currently tracks 13 actively recruiting clinical trials for sickle cell disease, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 13. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for sickle cell disease?
sickle cell disease research spans Phase 2 (4 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a sickle cell disease clinical trial?
Eligibility criteria for sickle cell disease trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
4
Phase 3
1
Top Sponsors
Forma Therapeutics, Inc. 2 trials
Assistance Publique - Hôpitaux de Paris 1 trial
Children's National Research Institute 1 trial
St. Jude Children's Research Hospital 1 trial
Hospital Universitari Vall d'Hebron Research Institute 1 trial

Recruiting Clinical Trials

NCT05953584 Phase 2
Recruiting
A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary Stroke
Enrollment
27 pts
Location
India, Nigeria, Oman
Sponsor
Forma Therapeutics, Inc.
View Trial →
NCT03976180
Recruiting
High-flow Oxygen for Vaso-occlusive Pain Crisis
Enrollment
350 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT05099874
Recruiting
Feasibility and Efficacy of Attentional-Control Training in Sickle Cell Disease
Enrollment
20 pts
Location
United States
Sponsor
Children's National Research I...
View Trial →
NCT05810181
Recruiting
Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)
Enrollment
145 pts
Location
United States
Sponsor
St. Jude Children's Research H...
View Trial →
NCT06198712 Phase 2
Recruiting
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
Enrollment
95 pts
Location
Canada, France, Keny...
Sponsor
Forma Therapeutics, Inc.
View Trial →
NCT07206095
Recruiting
Integrative Diagnosis for SCD and Other RADs
Enrollment
200 pts
Location
Spain
Sponsor
Hospital Universitari Vall d'H...
View Trial →
NCT03587272 Phase 2
Recruiting
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Enrollment
100 pts
Location
United States, Canad...
Sponsor
Robert Nickel
View Trial →
NCT03121001 Phase 2
Recruiting
Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
Enrollment
50 pts
Location
United States
Sponsor
University of Illinois at Chic...
View Trial →
NCT06691867
Recruiting
Integrative Training Program for Pediatric Sickle Cell Pain
Enrollment
155 pts
Location
United States
Sponsor
Emory University
View Trial →
NCT04398628
Recruiting
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Enrollment
3,000 pts
Location
United States
Sponsor
American Thrombosis and Hemost...
View Trial →
NCT05477563 Phase 3
Recruiting
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Enrollment
26 pts
Location
United States, Germa...
Sponsor
Vertex Pharmaceuticals Incorpo...
View Trial →
NCT05383911
Recruiting
Empowering Adolescents and Young Adults With Sickle Cell Disease as Partners in Treatment Decision Making (EMPOWER-AYA)
Enrollment
68 pts
Location
United States
Sponsor
Nemours Children's Clinic
View Trial →
NCT06035939
Recruiting
SMYLS Multi-site Trial
Enrollment
272 pts
Location
United States
Sponsor
Medical University of South Ca...
View Trial →

Related Conditions

thalassemia (2) attention deficit (1) cognitive deficit in attention (1) thalassaemia (1) congenital dyserythropoietic anemia cda (1) enzyme disorder anemia (1) spherocytosis hereditary (1) stomatocytosis (1) hemoglobin disorder (1) anemia due to membrane defect (1) rare anemia disorders (1) hematologic disorder (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology